Validation of sentinel lymph node dissection in prostate cancer: experience in more than 2,000 patients

Eur J Nucl Med Mol Imaging. 2009 Sep;36(9):1377-82. doi: 10.1007/s00259-009-1157-2. Epub 2009 May 9.


Purpose: Sentinel lymph node dissection (SLND) has replaced extended lymphadenectomy for nodal staging in several solid tumours. We present our results of SLND in prostate cancer in regard to detection and false-negative rate.

Methods: In a 2-day protocol about 300 MBq (99m)Tc-nanocolloid are injected into the prostate. Two hours later static scans of the pelvis are performed to get information about the number and location of radioactive lymph nodes. During surgery the radioactive nodes are excised with the help of a gamma probe and sent separately to the pathologist. The histological procedure includes haematoxylin and eosin staining, serial sections and immunohistochemistry.

Results: Since 1999, a total of 2,020 men underwent SLND alone or in combination with either standard or extended lymphadenectomy after radical retropubic prostatectomy. Lymph nodes positive for metastases were found in 16.7% of patients. The scintigraphic detection rate was 97.6% and the intraoperative detection rate 98%. For 187 lymph node-positive men who had either standard or extended lymphadenectomy in addition to SLND the false-negative rate could be calculated, resulting in false-negative findings in 11 of 187 patients (6%).

Conclusion: Our results demonstrate that SLND in prostate cancer is a reliable procedure for nodal staging.

Publication types

  • Clinical Trial

MeSH terms

  • False Negative Reactions
  • Humans
  • Lymph Node Excision*
  • Lymph Nodes / diagnostic imaging
  • Lymph Nodes / pathology
  • Lymph Nodes / surgery
  • Lymphatic Metastasis
  • Male
  • Prostatic Neoplasms / diagnostic imaging
  • Prostatic Neoplasms / pathology*
  • Prostatic Neoplasms / surgery
  • Radionuclide Imaging
  • Radiopharmaceuticals
  • Technetium


  • Radiopharmaceuticals
  • Technetium